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      1) The AET protected mice supralethally irradiated with gamma rays under high 
   dose rate were treated with isologous bone marrow (IBM) or homologous bone marrow 
  (HBM). The combined use of AET and IBM was effective for. saving the mice exposed 
  to supralethal irradiation, but most of the AET protected and HBM treated ones died 
  after the 21th post-irradiation day. 
      2) The AET protectedand gamma-irradiated donor HBM could not prevent delayed 
   death. 
                          INTRODUCTION 
    It is generally accepted that there are three types of acute radiation death 
 of mammals' ; they are characterized by hematopoietic failure, intestinal injuries 
 and central nervous system disorders. Bone marrow treatment which was first 
 observed by Lorenz et al.2,3) is available for hematopoietic failure, but less effec-
 tive for intestinal injuries and central nervous system disorders of supralethally 
 total body irradiated animals". On the other hand, several chemical radioprotec-
 tive agents are also known to protect the mammals from acute radiation death. 
 AET (S-2-isothiuronium dihydrobromide) 5`e) is one of the most effective ones 
 protecting animals, especially mice, from acute radiation death. AET has been 
 shown to protect intestines more than hematopoietic organs". Therfore, mice 
 pretreated with AET and exposed to total body irradiation of otherwise supra-
 lethal dose may survive acute radiation death when they receive inoculation of 
 bone marrow. Furthermore, it was suggested that AET protected predominantly 
 non-antibody forming cells8 . Therefore, recipient mice pretreated with AET and 
 exposed to supralethal dose of radiation may easily take homologous bone mar-
 row which is inoculated after irradiation, because prolonged complete wasting of 
 lymphoid tissues, in which immunologically competent cells are probably form-
 ed9,"o', of recipients is observed and reduced number of immunologically com-
 petent cells ameliorates homograft response. On the other hand, when bone mar-
 row of AET pretreated and irradiated homologous donor mice is inoculated to 
 recipient mice, they may not succumb to so-called secondary disease after total 
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body irradiation. Cudkowicz  reported11' that preirradiation of donor homologous 
bone marrow could prevent homologous disease as well as AET pretreated and 
X-irradiated donor marrow did. 
   In most of the experiments on bone marrow treatment, X rays were used to 
irradiate animals, but only a few12,13' have used gamma-rays under high dose 
rate. A powerful Co" gamma-irradiation facility has been furnished at our uni-
versity. Therefore, the purpose of this experiment is to ascertain whether the 
combined use of AET and bone marrow treatment of supralethally gamma-irra-
diated mice is effective, and whether AET pretreated and gamma-irradiated HBM 
(homologous bone marrow) can prevent the recipient mice from secondary disease 
after total body gamma-irradiation under high dose rate. 
                    MATERIALS AND METHODS
   1) Mouse : Dd/s strain mice supplied from the Kyoto University Animal 
Center were used as recipients and isologous bone marrow (IBM) donors. Na2 
strain mice were used as homologous bone marrow (HBM) donors. They were 
two to two and a half months old weighing 20-23 g. The sexes of the donors 
and recipients were identical. Irradiated mice were kept in wooden boxes me-
asuring 16 X 12 X30 cm, 8 to 10 in a box, were fed wheat, dried fish and vegetable 
and were given tap water ad libitum. 
   2) Preparation of cell suspension : The donor mice were sacrificed by cervi-
cal dislocation and bilateral femurs and tibias were removed aseptically. Both 
ends of the bones were cut, a small needle (size 1/5, used usually for tuberculin 
tests) was inserted into one end, cold sterile Tyrode's solution was flushed 
through the bone marrow cavity and bone marrow cells in it were washed out 
into a small tube. Coarse particles settled down by gravity within half a minute. 
   3) Irradiation : A Co" gamma-irradiation facility which belongs to the Insti-
tute for Chemical Research of Kyoto University was used in the present experi-
ments. The facility has been described in detail14,15'. The intensity of gamma 
rays in June 1962 was 139 kr/h, namely, 38.7 r/sec. which was quite high. LD 
100/30 day dose of 900r was obtained in 27 sec. in October 1962, and in 32 sec. 
in October 1964. 
   4) AET : AET was supplied from the Takeda Pharmaceutical Industry, 
Ltd., Osaka, Japan. The mice were intraperitoneally given AET (6.0-10.0 mg/ 
mouse) in physiological saline 15-20 minutes before irradiation. The bone mar-
row donor mice given AET were exposed to 100r, 450r or 900r 4 hours, 6 days 
or 8 days before sacrifice. In some instances, the donors without AET were ex-
posed to 100r, 450r or 900r 4 hours, 6 days or 8 days before sacrifice. 
                           RESULTS 
   I) Combined Use of AET and Bone Marrow Treatment for Irradiation In-
      juries 
   A) Survival rate. The survival rates and 30-day mortalities in 13 experi- 
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                   Table 1. Survival rate of  AET protected, gamma-irradiated mice 
                   treated with IBM* (or HBM)*. 
                                   Number°0 Survival at days          Exp.Treatment of mice 
                                   7 14 21 30 60 90 
       1 450r28100 100 100 100 93 93 
        2 AET-900r30100 100 86 86 86 86 
        3 900r-IBM28100 100 100 88 88 88 
        4 AET-900r=-IBM887 87 87 87 75 75 
    5 900r2040 0 
        6 AET-1300r1855 55 22 22 11 11 
        7 AET-1300-HBM1478 43 14 0 
       8 AET-1500r1777 65 23 6 6 6 
         9 AET-1500r-IBM 1573 73 66 60 60 60
         10 AET-1500r-HBM 12100 100 100 58 8 8 
      11 AET-1800r1414 0 
       12 AET-1800r-IBM 1527 6 0 
      13 AET-2000r150 
* Inoculated cell count is 10><106. 
      ments are shown in Table 1 and Fig. 1, respectively. At 900r, there were no 30-
      day survivals among the untreated mice, while the treated mice showed a signifi-
      cant percentage of survivals. At 1500r, survival rate of the AET alone treated 
      mice was 6% at 30 days, while those of the AET-IBM and AET-HBM treated 
      mice were 60% and 58% at 30 days, respectively. However, delayed death was 
      observed only in the AET-HBM treated mice, namely, survival rate at 90 days 
      was 8%. At 1800r or 2000r, all of the mice treated in any way died by 21 days. 
      They showed heavy bloody diarrhea and weight loss. 
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Fig, 1. Mortality of gamma-irradiated, AET protected mice treated with IBM. 
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            B) Body weight changes. Body weight changes are shown in Fig. 2. At 
         900r, body weight of the AET treated mice reached almost preirradiation level 
         by 30 days. In the AET-IBM treated mice body weight showed only a slight de-
         crease during the period of initial 10 days and then increased rapidly. At 1500r, 
         in most of the treated mice the weight loss stopped at 6 to 10 days, staying at 
         80-85% of preirradiation level in the AET-IBM treated mice and 70-75% in the 
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AET-HBM treated mice during the period of 90 days. At 1800-2000r, all of the 
treated mice died by 21 days, showing rapid weight loss. 
   C)  Hematological findings. 1) Leucocyte count. At 900r, as shown in Fig. 
3, peripheral blood leucocyte count in both the AET treated and the AET-IBM 
treated mice showed a rapid decrease, 2000 to 3000 at 2 days, 1000 at 3 days. In 
most of the irradiated and untreated mice there was no increase in leucocyte 
count up to the time of their death. In the AET or AET-IBM treated mice the 
leucocyte count began to increase at 5 or 6 days, the count being approximately 
3000 to 5000 at .6 days and 5000 to 9000 at 10 days. Thereafter, the count of the 
AET-IBM treated mice increased to the normal level somewhat quicker than that 
of the AET treated mice and both groups reached the normal level by 30 days. 
At 1500r, as shown in Fig. 4, changes of leucocyte count in the AET-IBM treat-
ed mice were essentially the same as those in them at 900r and in the AET-HBM 
treated mice. In the AET treated mice at 1500r, the leucocyte count showed a 
rapid decrease, 0 to 500 at 4 days, followed by a slight increase, but never reach-
ed 5000 by 21 days and most of the AET treated mice died by 30 days. 
   2) Erythrocyte count, reticulocyte count, platelet count and hemoglobin con-
tent. At 900r, the change of the erythrocyte count following irradiation was less 
than in the leucocyte count. As shown in Figs. 3 and 5, in both the AET-IBM 
treated and the AET treated mice changes of erythrocyte count, platelet count 
and hemoglobin content were almost the same. They showed a slight decrease 
for initial 10 to 20 days, followed by a gradual increase to reach the normal level 
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the  AET treated mice and the AET-IBM treated ones. The count in the former 
began to increase at 8 or 10 days, reaching its maximum at 20 days, while it in 
the latter began to increase at 5 to 7 days, reaching its maximum at 10 days. 
At 1500r, as shown in Fig. 4 and 6, there was a apparent difference between the 
AET treated and the AET-IBM treated mice. Erythrocyte and platelet count and 
hemoglobin content in the AET-IBM treated mice returned to normal by 30 days. 
In the AET treated mice the erythrocyte count and hemoglobin content decreased 
rapidly or gradually followed by a slight increase, but nerver reached normal by 
by 30 days and most of the mice died by 30 days. 
   D) Histological findings. 1) Bone marrow. At 900r, in both the AET treat-
ed and the AET-IBM treated mice only mature granulocytes, megakaryocytes and 
mononuclear cells were seen in the bone marrow cavity 24 hours after irradiation 
and the nucleated cell count of one femur was 3.0 x 106. These cells decreased 
in number to almost 1.4 X 106 at 3 days, but not to none. At 4 days many foci 
of young regenerating cells appeared in most of the AET-IBM treated mice and 
scattered groups of young cells appeared in most of the AET treated mice. Nu-
cleated cell count of one femur was 6.5 X106 in the former followed by return to 
the normal level by 8 days, and 3.0 x 106 in the latter followed by return to the 
normal level by 10 days. Autopsy on the AET treated mice that died between 
14 and 21 days revealed considerably regenerated bone marrow and some mice 
showed pneumonia of the lung and intestinal injuries, namely, destructed intestin-
al epithelial cells. At 1500r, in both the AET-IBM (or-HBM) treated mice, and 
the AET treated mice, the bone marrow showed incomplete wasting even at 3 
days, i.e., nucleated cell count of one femur was 0.8-1.0x106. And the early re-
generation of bone marrow in the former occurred at 4-5 days, while it in the 
latter occurred at 8-9 days. The former that died by 21 days showed a marked 
degeneration of the intestinal epithelium, but most of the bone marrow recovered 
to the normal level by 10-14 days. The complete recovery of bone marrow in 
the latter was observed at 24 days. At 1800r, all of the AET treated mice 
that died by 14 days died of intestinal injuries and showed no recovery of the 
hematopoietic systems. But a few mice of the AET-IBM treated ones that died 
between 11 and 21 days showed almost complete bone marrow recovery. 
   2) Spleen. At 900r, in both the AET-treated and the AET-IBM treated mice 
lymphocytes in the white pulp of the spleen rapidly decreased in number after 
irradiation, but disappearance from the red pulp of the cells of the erythrocytic 
and myelocytic series was incomplete at 2 days, and a small number of lympho-
cytes always remained in the white pulp. The marked regeneration of the cells 
of the erythrocytic and myelocytic series in the red pulp usually began at 6 to 7 
days and became nearly complete at 10 days in the AET-IBM treated mice. The 
white pulp of the AET-IBM treated mice did not recover earlier than that of the 
AET alone treated mice. At 1500r, in both the AET treated mice and the AET-
IBM (or-HBM) treated mice, the disappearance from the red pulp of the cells 
was not complete at 3-4 days. A marked regeneration of the red pulp in the 
latter occurred at 5-8 days, but that of the former did at 9-10 days. The white 
pulps in both groups were still nearly wasted at 30 days. 
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   3) Lymphnode. At 900r, the lymphnodes had wasted almost completely by 
24 hours after irradiation, leaving a small number of lymphocytes. In both groups 
these wasted conditions continued for about three weeks. In the AET-IBM treat-
ed mice the number of lymphocytes in the lymphnodes became almost normal by 
30 days, but in the AET treated mice it was still subnormal by 30 days. At 
1500r, in both groups the lymphnodes had wasted almost completely by 24 hours 
after irradiation and these conditions continued for 30 days. 
   4) Thymus. At 900r, complete wasting of the thymus was followed by a 
fairly good recovery at 5 to 9 days in some of the mice in both groups. At 1500r, 
complete wasting of the thymus was followed by recovery of the cortex at 7 to 
9 days in some of the mice in both groups. But the thymic recovery of the AET- 
HBM treated mice was not observed by 30 days. 
   5) Intestine. At 900r, slightly destructed villi and scattered vacuoles were 
seen in both groups but a marked degeneration could not be found. At 1500r, 
profound loss of the intestinal epithelium was found in some of the mice in all 
groups. At 1800r and 2000r, almost complete loss of the intestinal epithelium 
was found in most of both groups. 
   II) Effect of Treatment of AET Treated and Preirradiated Donor Marrow 
      on Lethally Whole Body Irradiated Mice 
   A) Survival rate. The survival rates in 16 experiments are shown in Table 
2. Both the 100r irradiated and the 6 days previously 100r irradiated HBM could 
not save well 900r irradiated host mice from early death, while the 6 days pre- 
  Table 2. Survival rate of lethally gamma-irradiated mice treated with IBM (or HBM) 
   from the mice given AET and varying doses of gamma rays. 
             DonorRecipient% Survival (at days) 
Exp. Treat- BM suspension at Treat- Number      T
ypement days after irrad. ment of mice7 14 21 30 60 90 
 1 HBM 100r0900r 12 63 18 18 18 9 9 
 2 HBM 100r6900r 12 66 16 16 16 16 16 
 3 IBM 100r6900r 12 66 66 66 66 66 66 
  4 IBM AET- 100r 0900r 12 100 100 100 83 83 83 
 5 HBM AET-100r 0900r 18 72 28 28 17 11 6 
  6 IBM AET- 100r 6900r 8 100 100 100 100 100 100 
  7 HBM AET- 100r 6900r 28 86 57 45 39 25 21 
 8 IBM AET-450r 0900r 12 66 50 50 50 50 50 
 9 HBM AET-450r 0900r 20 80 20 20 20 5 5 
 10 IBM AET- 450r 8900r 8 100 100 100 100 87 75 
 11 HBM AET-450r 8900r 7 14 0 
 12 HBM 450r0900r 11 65 18 18 18 9 9 
 13 HBM None None900r 20 60 80 20 20 10 10 
 14 IBM AET- 900r 8900r 7 14 14 14 14 14 14 
 15 IBM AET- 100r 6AET-1500r 8 75 75 75 75 75 63 
 16 HBM AET- 100r 6AET-1500r 14 93 78 57 50 50 36 
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viously 100r irradiated IBM could save well the mice from early death, i.e., 21-
day survival was 66%. Both the AET protected, 100r preirradiated IBM and the 
AET protected, 6 days previously 100r irradiated HBM could save early death 
fairly well, giving slightly increased survival rates. They were 100% and 45% 
at 21 days in the former and the latter group, respectively, but were 83% and 
21% at 90 days, respectively. Both the AET protected and 100r irradiated HBM 
and the AET protected and 8 days previously 450r irradiated HBM could not save 
well the mice from early death. The AET protected and 1500r irradiated mice 
transplanted with the AET protected and 6 days previously 100r irradiated HBM 
showed a fairly good survival rate, i.e., 57% at 21 days, but the similarly treat-
ed host mice infused with AET protected and 6 days previously 100r irradiated 
IBM showed a good survival, i.e., 75% at 21 days and 63% at 90 days. 
   B) Body weight. There were no differences in the body weight between the 
mice treated with ordinary bone marrow and the one infused with pretreated 
bone marrow. 
   C) Hematological findings. There were not so much differences between the 
mice treated with ordinary bone marrow and the ones infused with pretreated 
bone marrow. As shown in Fig. 7, effectiveness of the AET protected and 6 days 
previously 100r irradiated IBM is stronger than that of the HBM treated in the 
same way. 
   D) Histological findings. There were not so much differences between the 
mice treated with ordinary bone marrow and the ones infused with pretreated 
bone marrow. 
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                         DISCUSSION 
   It was first observed by Jacobson et  al.16,17> that shielding of the spleen of 
mice protected them from acute radiation death. Thereafter, Lorenz et al.20> 
demonstrated that the mice exposed to lethal total body irradiation were protect-
ed by inoculation of bone marrow cells. Bone marrow treatment is effective for 
radiation injury by a lethal dose, namely, for hematopoietic failure, and can not 
save most of the mice that have received supra-lethal dose of total body irradia-
tion in which intestinal damage plays a major role. Makinodan et al.18> reported 
that percent survival of the mice exposed to 1300r and treated with IBM was 
lower than that of the ones exposed to 900r lethal irradiation and treated with 
IBM and we also observed19> that all of the mice exposed to 1300r-1500r and 
treated with IBM died by 21 days due mainly to intestinal damage, though some 
mice showed good hematopoietic recovery at early post-irradiation days. On the 
other hand, a chemical radioprotective compound AET is known to protect both 
hematopoietic organs and intestinal tract. Doherty et al.7> reported that the pro-
tective effect of AET was stronger on the intestines than on the hematopoietic 
system. Then, the combined use of AET and bone marrow treatment might save 
most of the recipient mice which should die due to intestinal damage after total 
body irradiation of otherwise supralethal dose. One of the purposes of these ex-
periments reported here was to clarify the effect of the combined use of AET and 
bone marrow treatment under varying doses of total body irradiation. The sur-
vival rate of the AET treated mice exposed to 1500r total body irradiation was 
6% at 30 days after irradiation, but apparently it was raised to 60% at 30 days 
if the mice were treated with IBM, i.e., the combined use of AET and IBM could 
save most of the mice exposed to 1500r from radiation death, though the survivors 
at 90 days after irradiation still had reduced body weights which were appro-
ximately 80-90% of preirradiation level. When irradiation dose was increased to 
1800r-2000r, irradiated mice died of acute intestinal damage, even with the com-
bined treatment of AET and IBM, showing heavy diarrhea and pancytopenia. 
AET protected and supralethally irradiated mice treated with HBM showed a 
somewhat different clinical course, i.e., all of the AET-HBM treated mice at 
1300r died by 30 days, showing weight loss and diarrhea. This indicates that 1300r 
was not a supralethal dose, but sublethal to the AET protected mice, and then 
HBM inoculation gave lethal effect2°-23>, which was often observed in ordinary 
HBM or HSC (homologous spleen cells) transplantation to sublethally irradiated 
mice, to the recipient mice. Most of the AET-HBM treated mice at 1500r surviv-
ed for 30 days, but later they died by 60 days, showing still weight loss and diar-
rhea. Although most of the AET-IBM treated mice survived beyond 90 days, 
their body weight still did not reach the preirradiation level by 90 days. In the 
long term observations of IBM treated mice, a few workers13,24> reported that the 
mice exposed to lethal irradiation and saved with bone marrow treatment had 
somewhat different manifestations from the unirradiated control mice, which in-. 
cluded retarded increase of body weight, occurrence of some malignant neoplasms 
and nephrosclerosis. Therefore, it is probable that the survivors exposed to su-
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                Explanation of Plates 
Plate 1. Small intestine ; 3 days after 1500r irradiation. Marked  de-
 generation of intestinal epithelium. 
Plate 2. Bone marrow ; 4 days after 1500r irradiation in the mouse 
 given AET and HBM. The bone marrow cavity is filled with neutro-
 phile leucocytes and the spotty early regeneration is observed. 
Plate 3. Bone marrow ; Higher magnification of Fig. 2. Many neutro-
 phile leucocytes and spotty young cells. 
Plate 4. Spleen; 4 days after 1500r irradiation in the mouse given 
 AET and HBM. Complete wasting of the white pulp, but sparse 
 myelocytic and erythrocytic ceIls in the red pulp. 
Plate 5. Mesenteric lymphnode ; 4 days after 1500r irradiation in the 
 mouse given AET and HBM. Almost complete wasting. 
Plate 6. Thymus ; 6 days after 100r irradiation and AET protection. 
 Almost complete recovery. Nucleated cell count of one femur is 12x 
 106 in this mouse. 
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pralethal irradiation and treated with AET-IBM (or-HBM) beyond 90 days suffer-
ed from chronic radiation injuries, after they were saved from acute radiation. 
death. Histological studies on the AET pretreated mice at 4 days after 1500r ir-
radiation showed that the bone marrow was not completely acellular and the 
white pulp of the spleen was wasted while the red pulp of the spleen was not. 
completely wasted. Futhermore, damage to the lymph nodes was considerable. 
These findings also suggest that AET may protect predominantly non-antibody 
forming cells. It is suggested, at least, that the AET pretreated host exposed to 
1500r irradiation could easily take HBM without early mortality and would not 
succumb to secondary bone marrow aplasia which was thought to be a main 
cause of early mortality24,25) caused by host against graft reaction. On the other 
hand, even though the AET treated host exposed to supralethal irradiation could 
take inoculation of HBM easily, the repopulated immunologically competent cells. 
from the donor mice in the host might react, according to the graft against host. 
theory, against the host during the delayed stages after irradiation and trans-
plantation of HBM. Therefore, in order to suppress so-called secondary disease, 
the donor's bone marrow must be pretreated. Cudkowicz reportedl" that pre-
treatment with Xrays on the donor mice prevented delayed death. The data 
reported here have so far been different from his results. In this present experi- 
ment, a dose as small as 100r or 450r gamma-rayirradiated HBM could not pre-
vent even early death effectively. It has been observed by many investigators 
that D37 value is about 70r-115r26 30 Therefore, there might still be a small 
number of immunologically competent cells in the bone marrow when a radiation 
dose of 100r was given to the donor mice, and they might react against host 
antigens, even if pretreated HBM could prevent early death. Only the AET pro-
tected, 6 days previously 100r irradiated donor marrow showed 57% survival at 
14 days and 45% at 21 days, but the recipient mice also succumbed to delayed 
death after the 30th post-irradiation day. Therefore, such pretreated HBM had 
the proliferative ability, but failed to prevent so-called homologous disease. Argyris 
reported"' that the 400r irradiated HSC reduced the proliferative capacity of CBA 
spleen cells by about 95-96% and the immunologic activity by about 98-99%. In 
his studies a quantitative estimate was made of the decrease in proliferative 
capacity and immunologic activity of spleen cells exposed to 400r of total body 
X-irradiation. The decreased proliferative capacity of irradiated CBA spleen cells 
was inferred from a decreased ability to induce homograft tolerance in newborn 
C3H mice as compared to the ability of various doses of non-irradiated CBA spleen 
cells to induce homograft tolerance. The decreased immunologic activity of CBA 
spleen cells was estimated from a decreased capacity to induce a graft against 
host reaction in newborn C57BL/6 mice as compared to the capacity of standard 
doses of non-irradiated CBA cells. Makinodan281 found an approximate 98% de-
crease in antibody producing capacity in terms of agglutinin production after 400r 
total body X-irradiation. Celada and Carter29' reported that at lower doses of X-
irradiation in vit"o the homograft rejecting mechanism of mouse spleen cells is 
more radio-resistant than the agglutinin producing capacity. On the other hand, 
Goodman and Bender32' reported that the radiosensitivity of immunologically corn-
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petent cells was similar to that of hematopoietic cells and 400r irradiated HBM 
could not prevent secondary disease in the strain combination of 1C3F1 and LAF1 
or B6D2F1. In the present study the 450r gamma-irradiated HBM could not  pre-
vent even early death in the strain combination of Na2 and Dd/s and only the 
AET protected, 6 days previously 100r irradiated HBM could prevent early death, 
though they failed to prevent delayed death. Furthermore, the AET-IBM treated 
mice exposed to supralethal irradiation survived for 90 days, while most of the 
AET-HBM treated mice exposed to 1500r irradiation died after the 30th post-
irradiation day. 
   To summarize, it has been thought that AET protects non-antibody forming 
cells predominantly, but its ability was found to be very weak, and the combined 
use of AET and bone marrow treatment in supralethally gamma-irradiated mice 
improved survival rates to a certain extent, whereas the AET pretreated and 
gamma-irradiated HBM could not prevent the recipient mice from delayed death 
after total body gamma-irradiation under high dose rate. 
   In order to prevent so-called secondary disease compeletely, further funda-
mental problems must be solved. 
                       ACKNOWLEDGMENTS 
   It is a great pleasure to thanks Professor G. Wakisaka, M. D. and Dr. H. 
Uchino, M. D. and Dr. M. Yamagishi, and Dr. M. Hama for their valuable sug-
gestions and advices in carrying out the study here reported. Thanks are also 
extended to Mr. R. Katano, Institute for Chemical Research of Kyoto University, 
for his kindness in frequently operating the Co" irradiation facility. 
   This work was supported by a grant-in-aid from the International Atomic 
Energy Agency 138/RB (1962-1964), to which thanks are due. 
                          REFERENCES 
 (1) L. H. Simith and C. C. Congdon, "Radiation Protection and Recovery" (Edited by A. 
    Hollaender), 7, 242, Pergamon Press, Oxford, 1960. 
 (2) E. Lorenz, D. Uphoff, T. R. Ried and E. Shelton, J. Nat. Cancer Inst., 12, 197 (1951). 
 (3) E. Lorenz, C. Congdon and D. Uphoff, Radiology, 58, 863 (1952).
 (4) C. C. Congdon, Blood, 12, 746 (1957). 
 (5) L. H. Smith, Exp. Cell Research, 13, 627 (1957). 
 (6) M. P. Dacquisto and E. W. Blackbur, Nature, 190, 270 (1961). 
 (7) J. R. Maisin and D. G. Doherty, Radiation Res., 19, 474 (1963). 
 (8) T. Makinodan, I. C. Shekarchi and C. C. Congdon, J. Imm., 79, 281 (1957). 
 (9) J. F. A. P. Miller, Ann. N. Y. Acad. Sci., 99, 340 (1962). 
(10) M. Hanaoka and T. Masuda, Ann. Report Inst. Virus Res. Kyoto University, 5, 170 
    (1962). 
(11) G. Cudkowicz, Proc. Soc. Exp. Biol. Med., 107, 821 (1961). 
(12) M. Yamagishi, This Bulletin, 37, 440 (1959). 
(13) H. Uchino and M. Yamagishi, Ada Haem. Jap., 24, 656 (1961). 
(14) S. Okamoto and Y. Nakayama, This Bulletin 37, 299 (1959). 
(15) S. Shimizu, S. Tanaka and Y. Nakayama, This Bulletin, 37, 306 (1959). 
(16) L. O. Jacobson, E. K. Marks, E. O. Gaston, M. Robson and R. E. Zirble, Proc. Soc. 
    Exp. Biol. Med., 70, 740 (1949). 
(101)
                              Kazushige ADACHI 
(17) L. 0. Jacobson, E. L. Simmons,  E. K. Marks and J. H. Eldredge, Science, 113, 510 
   (1951). 
(18) N. Gengozian and T. Makinodan, Cancer Res., 17, 970 (1957). 
(19) K. Adachi, Unpublished data. 
(20) E. G. Schwartz, A. C. Upton and C. C. Congdon, Proc. Soc. Ext. Biol. Med., 96, 797 
   (1957). 
(21) N. Gengozian and T. Makinodan, J. Imm., 77, 430 (1956). 
(22) D. E. Uphoff, J. Nat. Cancer Inst., 30, 1115 (1963). 
(23) K. Adachi, This Bullebin, 44, 103 (1966). 
(24) M. J. de Vries and 0. Vos, J. Nat. Cancer Inst., 23, 1403 (1959). 
(25) J. J. Trentin, Ann. N. Y. Acad. Sci., 73, 799 (1958). 
(26) E. A. McCulloch and J. E. Till, Radiation Res., 13, 115 (1960). 
(27) J. E. Till and E. A. McCulloch, Radiation Res., 14, 213 (1961). 
(28) T. Makinodan, M. A. Kastenbaum and W. J. Peterson, J. Imm., 88, 31 (1962). 
(29) F. Celada and R. R. Carter, J. Imm., 89, 161 (1962). 
(30) L. H. Smith and 0. Vos, Radiation Res., 19, 485 (1963). 
(31) B. F. Argyris, Transplantation, 1, 488 (1963). 
(32) J. W. Goodman and M. A. Bender Transplantation, 2, 334 (1964). 
(102)
